English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 25 November 2020, 14:00 HKT/SGT

Source: Brawijaya University
Brawijaya University develops GAD65 Rapid Test Diabetes Screening Kit

Malang, East Java, Indonesia, Nov 25, 2020 - (ACN Newswire) - Brawijaya University (UB) in Malang, East Java has developed an initial screening kit for diabetes. The Bioscience Rapid Test GAD65, developed by aresearch team led by Prof. Dr. Aulanni'am, drh, DES, is ready for commercialization and use in early screening for Type I Diabetes Mellitus, before measures and treatment are determined.

The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults (LADA).

Diabetes is a global health threat which can lead to complications that impact the quality of human life as well as substantially add to health costs for families and countries. Its increasing prevalence has raised concerns globally and prompted prevention efforts. Detecting and managing the condition through appropriate therapy is crucial for preventing deterioration in the condition of people suffering from the metabolic disease.

The Bioscience Rapid Test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya University and state-owned pharmaceutical company PT Bio Farma (Persero). The preparation and production of the kit has involved various levels of research and testing, based on the consensus and regulations set by the World Health Organization (WHO) and the Indonesian Health Ministry.

The screening kit, which has a medical device distribution permit and meets the certification requirements for good medical device manufacturing from the Indonesian Ministry of Health, is ready to be produced and widely distributed and has been introduced to potential consumers in Spain, Taiwan, Japan, Saudi Arabia, Jordan, Madagascar, the Philippines, and Malaysia.

As part of the collaboration for the downstreaming process of the kit, Brawijaya University has been designated as the producer and PT Bio Farma as the main distributor of the patented product (ID. 0.022.556 B, 2009-Granted and P00201910578, 2019-Registered).

For further information, please contact:
Prof Dr. Aulanni'am, drh., DES
+62 812-3317-600
Public Relations,
Universitas Brawijaya

Topic: Press release summary
Source: Brawijaya University

Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Brawijaya University Related News
Aug 11, 2023 17:00 HKT/SGT
Indonesia's first 8K uncompressed video conference inaugurates 100 Gbps network for education at UB-Universitas Brawijaya
June 7, 2023 18:00 HKT/SGT
Brawijaya-Japan cooperate to establish Research Center of Robotic, AI
Sept 30, 2022 17:00 HKT/SGT
Brawijaya University develops GIS-based IoT for disaster mitigation
Apr 4, 2022 07:00 HKT/SGT
Brawijaya Student Start-up makes Forbes 30 Under 30 List
Nov 25, 2021 04:00 HKT/SGT
Universitas Brawijaya developing digital halal certification system for Indonesian MSMEs
More news >>
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575